Glucocorticoid‐Induced Leucine Zipper (GILZ) Controls Inflammation and Tissue Damage after Spinal Cord Injury

Spinal cord injury (SCI) occurs following damage to the spinal column. Following trauma, tissue damage is further exacerbated by a secondary damage due to a SCI‐activated inflammatory process. Control of leukocytes activity is essential to therapeutic inhibition of the spinal cord damage to ameliorate the patient's conditions. The mechanisms that regulate neuroinflammation following SCI, including T‐cell infiltration, have not been completely clarified. Glucocorticoids (GC) are antiinflammatory drugs widely used in therapy, including treatment of SCI. GC efficacy may be linked to many molecular mechanisms that are involved in regulation of leukocytes migration, activation, and differentiation. We have previously shown that the antiinflammatory activity of GC is in part mediated by glucocorticoid‐induced leucine zipper (GILZ). Here, we investigated the role of GILZ in inflammation and spinal cord tissue damage following a spinal trauma.

[1]  T. B. Jones,et al.  Lymphocytes and autoimmunity after spinal cord injury , 2014, Experimental Neurology.

[2]  C. Riccardi,et al.  GILZ promotes production of peripherally induced Treg cells and mediates the crosstalk between glucocorticoids and TGF-β signaling. , 2014, Cell reports.

[3]  I. Stojanovic,et al.  IL‐17 and Glutamate Excitotoxicity in the Pathogenesis of Multiple Sclerosis , 2014, Scandinavian journal of immunology.

[4]  K. Takeda,et al.  ifn-γ-dependent secretion of IL-10 from Th1 cells and microglia/macrophages contributes to functional recovery after spinal cord injury , 2013, Cell Death and Disease.

[5]  L. Facci,et al.  Microglia and mast cells: two tracks on the road to neuroinflammation , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  T. Atsumi,et al.  Interleukin-1 participates in the classical and alternative activation of microglia/macrophages after spinal cord injury , 2012, Journal of Neuroinflammation.

[7]  B. Xiao,et al.  Anti-Inflammatory Effect of Erythropoietin Therapy on Experimental Autoimmune Encephalomyelitis , 2012, The International journal of neuroscience.

[8]  M. Fuggetta,et al.  Anti-inflammatory Effect of Resveratrol and Polydatin by In Vitro IL-17 Modulation , 2012, Inflammation.

[9]  E. Mazzon,et al.  Glucocorticoid-Induced Leucine Zipper (GILZ) Over-Expression in T Lymphocytes Inhibits Inflammation and Tissue Damage in Spinal Cord Injury , 2011, Neurotherapeutics.

[10]  C. Riccardi,et al.  Long Glucocorticoid-induced Leucine Zipper (L-GILZ) Protein Interacts with Ras Protein Pathway and Contributes to Spermatogenesis Control* , 2011, The Journal of Biological Chemistry.

[11]  G. Giardino,et al.  Efficacy of very‐low‐dose betamethasone on neurological symptoms in ataxia‐telangiectasia , 2011, European journal of neurology.

[12]  P. Popovich,et al.  Emerging Concepts in Myeloid Cell Biology after Spinal Cord Injury , 2011, Neurotherapeutics.

[13]  Gila Moalem-Taylor,et al.  Interleukin-17 contributes to neuroinflammation and neuropathic pain following peripheral nerve injury in mice. , 2011, The journal of pain : official journal of the American Pain Society.

[14]  C. Gorrie,et al.  Interleukin-17 deficiency improves locomotor recovery and tissue sparing after spinal cord contusion injury in mice , 2011, Neuroscience Letters.

[15]  C. Riccardi,et al.  Glucocorticoid-induced Leucine Zipper (GILZ) and Long GILZ Inhibit Myogenic Differentiation and Mediate Anti-myogenic Effects of Glucocorticoids* , 2010, The Journal of Biological Chemistry.

[16]  C. Riccardi,et al.  Glucocorticoid‐induced leucine zipper (GILZ): a new important mediator of glucocorticoid action , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  E. Mazzon,et al.  Glucocorticoid-induced leucine zipper is protective in Th1-mediated models of colitis. , 2009, Gastroenterology.

[18]  L. Ellestad,et al.  Expression and regulation of glucocorticoid-induced leucine zipper in the developing anterior pituitary gland. , 2008, Journal of molecular endocrinology.

[19]  C. Ferrari,et al.  Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease , 2008, Brain : a journal of neurology.

[20]  Qingli Xiao,et al.  Methylprednisolone Protects Oligodendrocytes But Not Neurons after Spinal Cord Injury , 2008, The Journal of Neuroscience.

[21]  P. Popovich,et al.  Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury , 2008, Experimental Neurology.

[22]  K. Hayes,et al.  Clinical correlates of elevated serum concentrations of cytokines and autoantibodies in patients with spinal cord injury. , 2007, Archives of physical medicine and rehabilitation.

[23]  Serge Rossignol,et al.  Spinal Cord Injury: Time to Move? , 2007, The Journal of Neuroscience.

[24]  H. Yoshikawa,et al.  Localization of glucocorticoid-induced leucine zipper (GILZ) expressing neurons in the central nervous system and its relationship to the stress response , 2007, Brain Research.

[25]  K. Takagishi,et al.  Effects of the Second National Acute Spinal Cord Injury Study of High-Dose Methylprednisolone Therapy on Acute Cervical Spinal Cord Injury–Results in Spinal Injuries Center , 2006, Spine.

[26]  E. Mazzon,et al.  Increased GILZ expression in transgenic mice up-regulates Th-2 lymphokines. , 2006, Blood.

[27]  C. Riccardi,et al.  Genomic and non-genomic effects of different glucocorticoids on mouse thymocyte apoptosis. , 2006, European journal of pharmacology.

[28]  J. Cidlowski,et al.  Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. , 2005, The New England journal of medicine.

[29]  A. Członkowska,et al.  Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. , 2004, International immunopharmacology.

[30]  J. Grauer,et al.  Pathophysiology and pharmacologic treatment of acute spinal cord injury. , 2004, The spine journal : official journal of the North American Spine Society.

[31]  K. Satoh,et al.  Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson’s disease , 2003, Journal of neurology, neurosurgery, and psychiatry.

[32]  M. Hart,et al.  Activated/effector CD4+ T cells exacerbate acute damage in the central nervous system following traumatic injury , 2003, Journal of Neuroimmunology.

[33]  A. Foussat,et al.  Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10. , 2003, Blood.

[34]  M. Schwartz,et al.  Myelin specific Th1 cells are necessary for post-traumatic protective autoimmunity , 2002, Journal of Neuroimmunology.

[35]  K. Hayes,et al.  Elevated serum titers of proinflammatory cytokines and CNS autoantibodies in patients with chronic spinal cord injury. , 2002, Journal of neurotrauma.

[36]  C. Riccardi,et al.  Molecular mechanisms of immunomodulatory activity of glucocorticoids. , 2002, Pharmacological research.

[37]  P. Popovich,et al.  Alterations in immune cell phenotype and function after experimental spinal cord injury. , 2001, Journal of neurotrauma.

[38]  C. Riccardi,et al.  Modulation of T-cell activation by the glucocorticoid-induced leucine zipper factor via inhibition of nuclear factor kappaB. , 2001, Blood.

[39]  M. Farooque,et al.  White matter preservation after spinal cord injury in ICAM-1/P-selectin-deficient mice , 2001, Acta Neuropathologica.

[40]  C. Riccardi,et al.  Cloning, chromosomal assignment and tissue distribution of human GILZ, a glucocorticoid hormone-induced gene , 2001, Cell Death and Differentiation.

[41]  C. Hulsebosch,et al.  Bridging the gap: from discovery to clinical trials in spinal cord injury. , 2000, Journal of neurotrauma.

[42]  E. Agranov,et al.  Passive or Active Immunization with Myelin Basic Protein Promotes Recovery from Spinal Cord Contusion , 2000, The Journal of Neuroscience.

[43]  R. Kofler,et al.  The molecular basis of glucocorticoid-induced apoptosis of lymphoblastic leukemia cells , 2000, Histochemistry and Cell Biology.

[44]  P. Cui,et al.  Chymase is a potent chemoattractant for human monocytes and neutrophils , 2000, Journal of leukocyte biology.

[45]  M. Schwartz,et al.  Innate and adaptive immune responses can be beneficial for CNS repair , 1999, Trends in Neurosciences.

[46]  M. Farooque,et al.  Improved recovery after spinal cord trauma in ICAM-1 and P-selectin knockout mice. , 1999, Neuroreport.

[47]  C. Riccardi,et al.  A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death. , 1997, Immunity.

[48]  S. Kushimoto,et al.  Role of neutrophils in spinal cord injury in the rat , 1997, Neuroscience.

[49]  H. Winn,et al.  Administration of Methylprednisolone for 24 or 48 Hours or Tirilazad Mesylate for 48 Hours in the Treatment of Acute Spinal Cord Injury Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial , 1997 .

[50]  V. Perry,et al.  Lymphocyte Recruitment Following Spinal Cord Injury in Mice is Altered by Prior Viral Exposure , 1997, The European journal of neuroscience.

[51]  C. Whitacre,et al.  Concept of autoimmunity following spinal cord injury: Possible roles for T lymphocytes in the traumatized central nervous system , 1996, Journal of neuroscience research.

[52]  J. Bach,et al.  Immunosuppressive therapy of autoimmune diseases. , 1993, Trends in pharmacological sciences.

[53]  Hoffman Gs.  Immunosuppressive therapy for autoimmune diseases. , 1993 .

[54]  W. Collins,et al.  A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. , 1991, The New England journal of medicine.

[55]  H. Winn,et al.  Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. , 1997, JAMA.

[56]  W. Collins,et al.  Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second National Acute Spinal Cord Injury Study. , 1992, Journal of neurosurgery.